(NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

The company’s fourth-quarter numbers also covered the first full quarter following the launch of Guardant’s Shield blood test for colorectal cancer screening, following its approval by the FDA ...

Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer. Guardant, a biotechnology company, provides a blood ...

announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield test. The agreement ...

Investing.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has ...

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer Guardant Health, Inc. (Nasdaq ...

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...